Effect of Bevacizumab in advanced low grade serous ovarian cancer
Effect of Bevacizumab in advanced low grade serous ovarian cancer

Effect of Bevacizumab in advanced low grade serous ovarian cancer

The study was to explore the efficacy of Bevacizumab (Bev) on survival outcomes in advanced low-grade serous ovarian cancer (LGSOC) both in the first line and in the recurrent setting. The results suggested that Bev was effective in LGSOC both at diagnosis and at the time of relapse.

要查看或添加评论,请登录

Connect2Clinic的更多文章

社区洞察

其他会员也浏览了